Blood production depends on rare haematopoietic stem cells (HSCs) and haematopoietic
stem and progenitor cells (HSPCs) that ultimately take up residence in the bone marrow …

Cancer is a complex disease in which several molecular and cellular pathways converge to
foster the tumoral phenotype. Notably, in the latest iteration of the cancer hallmarks,“ …

Clonal hematopoiesis (CH) arises when hematopoietic stem cells (HSCs) acquire mutations,
most frequently in the DNMT3A and TET2 genes, conferring a competitive advantage …

Age is a major risk factor for cancer, but how aging impacts tumor control remains unclear. In
this study, we establish that aging of the immune system, regardless of the age of the stroma …

Myeloid malignancies are devastating hematologic cancers with limited therapeutic options.
Inflammation is emerging as a novel driver of myeloid malignancy, with important …

Individuals with clonal hematopoiesis of indeterminate potential (CHIP) are at increased risk
of aging related health conditions and all-cause mortality, but whether CHIP affects risk of …

Canakinumab, a monoclonal antibody targeting proinflammatory cytokine interleukin-1β (IL-
1β), improved hemoglobin levels while preventing recurrent cardiovascular events in the …

Clonal hematopoiesis (CH) is a common premalignant state in the blood and confers an
increased risk of blood cancers and all-cause mortality. Identification of therapeutic targets in …

With aging, hematopoietic stem cells (HSCs) have an impaired ability to regenerate,
differentiate, and produce an entire repertoire of mature blood and immune cells. Owing to …

Tissue inflammation is a hallmark of tumour microenvironments. In the bone marrow, tumour-
associated inflammation impacts normal niches for haematopoietic progenitor cells and …